Drug intelligence / Profile preview

SPT-3202

Development stage: Preclinical
Lead developer: Seaport Therapeutics
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Administration: Oral

Overview

SPT-3202 is a clinical-stage oral prodrug of agomelatine, developed by Seaport Therapeutics. It is being advanced for the treatment of generalized anxiety disorder and utilizes the Glyph platform for oral delivery to the lymphatic system. Its active component, agomelatine, functions as an agonist at melatonin MT1 and MT2 receptors and an antagonist at serotonin 5-HT2C and 5-HT2B receptors.

Targets

HTR2C (5-hydroxytryptamine 2C receptor)HTR2B (5-Hydroxytryptamine Receptor 2B)MTNR1A (MT1)MTNR1B (Melatonin Receptor 2)

Beyond the preview

Go deeper on SPT-3202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPT-3202.

Explore the full profile